Aprea Therapeutics, Inc. (APRE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aprea Therapeutics, Inc. on January 13, 2025. The filing primarily serves to disclose updated financial information regarding the Company's liquidity position as of December 31, 2024, which was presented in a corporate slide deck posted to the Company's website.
Key Financial Metrics
- Cash and Cash Equivalents: $22,800,000 as of December 31, 2024.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, net income, operating margins, or cash flow for the period.
- Debt and Liquidity: No specific debt figures are disclosed in this filing; liquidity is represented solely by the cash balance noted above.
Material Changes
The filing does not provide comparative financial data for the prior period (e.g., December 31, 2023) to determine material changes in cash balances or other metrics. The disclosure focuses on the current cash position as of the end of the 2024 fiscal year.
Guidance, Outlook, and Risks
The financial information disclosed is unaudited and preliminary. The Company explicitly states that this data does not present all information necessary for a full understanding of its financial condition and remains subject to the completion of the audited financial statements for the fiscal year ended December 31, 2024. The information in this 8-K is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the final audited cash balance in the upcoming Form 10-K for the fiscal year ended December 31, 2024.
- Review the full Corporate Presentation (Exhibit 99.1) for additional context on cash burn rates or funding plans not detailed in the 8-K text.
- Confirm the absence of undisclosed debt obligations by reviewing the full 10-K once filed.